Brepocitinib Beneficial for Moderate-to-Severe Psoriatic Arthritis
Elana Gotkine
THURSDAY, May 18, 2023 (HealthDay News) -- For patients with moderately to severely active psoriatic arthritis, the tyrosine kinase…
Browsing Tag
Brepocitinib
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies…
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically…
Brepocitinib Shows Promise in Phase II Trial for PsA
The oral tyrosine kinase 2/Janus kinase 1 inhibitor brepocitinib showed efficacy for psoriatic arthritis (PsA) in a phase IIb trial.…